Cargando…
Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
SIMPLE SUMMARY: Only 10–20% of patients with newly diagnosed resectable pancreatic adenocarcinoma have potentially resectable disease. Upfront surgery is the gold standard, but it is rarely curative. After surgical extirpation of tumors, up to 80% of patients will develop cancer recurrence, and the...
Autores principales: | Lambert, Aurélien, Schwarz, Lilian, Ducreux, Michel, Conroy, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469083/ https://www.ncbi.nlm.nih.gov/pubmed/34572951 http://dx.doi.org/10.3390/cancers13184724 |
Ejemplares similares
-
An update on treatment options for pancreatic adenocarcinoma
por: Lambert, Aurélien, et al.
Publicado: (2019) -
Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021) -
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
por: Heinrich, Stefan, et al.
Publicado: (2019) -
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020) -
Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)